Tumor Metrics: 13.3% of the incidence of ESC was inhibited by ATV. A marked decrease in the volume and weight of the tumors in mice given the ATV vaccination.Immunological Response: In ESC, there are more CD8+ T cells and fewer FOXP3+ Treg cells, which have a considerable antiangiogenic function and an elevated CD8+/Treg ratio. The gene discussed is FOXP3; the disease is neoplasm.